Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
Find more results for teva
-0.15 (-0.47%)
Apr 28 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 31.30 - 31.94
52 week 30.22 - 56.44
Open 31.94
Vol / Avg. 5.03M/5.90M
Mkt cap 31.80B
P/E 203.85
Div/yield 0.34/4.31
EPS 0.15
Shares 1.01B
Beta 0.63
Inst. own 65%
May 11, 2017
Q1 2017 Teva Pharmaceutical Industries Ltd Earnings Call - 8:00AM EDT - Add to calendar
May 11, 2017
Q1 2017 Teva Pharmaceutical Industries Ltd Earnings Release - 7:00AM EDT - Add to calendar
Apr 18, 2017
Teva Pharmaceutical Industries Ltd Annual Shareholders Meeting (Estimated)
Mar 15, 2017
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference - Webcast
Mar 8, 2017
Teva Pharmaceutical Industries Ltd at Cowen Health Care Conference
Feb 13, 2017
Q4 2016 Teva Pharmaceutical Industries Ltd Earnings Call
Feb 13, 2017
Q4 2016 Teva Pharmaceutical Industries Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -14.96% 1.38%
Operating margin -2.11% 5.80%
EBITD margin - 30.72%
Return on average assets -4.06% 0.41%
Return on average equity -13.60% 0.24%
Employees 56,960 -
CDP Score - A-


5 Basel St., P.O. Box 3190
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Officers and directors

Yitzhak Peterburg Interim President and Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Eyal Desheh Group Executive Vice President, Chief Financial Officer
Age: 65
Bio & Compensation  - Reuters
Dipankar Bhattacharjee President and Chief Executive Officer - Global Generic Medicines Group
Age: 55
Bio & Compensation  - Reuters
Carlo De Notaristefani President and Chief Executive Officer, Global Operations
Age: 58
Bio & Compensation  - Reuters
Robert Koremans President, Chief Executive Officer - Global Specialty Medicines
Age: 54
Bio & Compensation  - Reuters
Iris Beck-Codner Group Executive Vice President - Corporate Marketing Excellence and Communication
Age: 50
Bio & Compensation  - Reuters
Mark Sabag Group Executive Vice President, Human Resources
Age: 45
Bio & Compensation  - Reuters
Timothy R. Wright Executive Vice President, Business Development, Strategy and Commercial Innovation
Age: 58
Bio & Compensation  - Reuters
Michael R. Hayden President - Global Research and Development, Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
David M Stark Chief Legal Officer
Bio & Compensation  - Reuters